Introducing the Galleri multi-cancer early detection test
Galleri is a blood test that can detect 50+ cancer types and can be taken annually.1,2
The Galleri test is available by prescription only. The Galleri test does not detect a signal for all cancers, and false positive or false negative results can occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.
Patient Story: Roger, Cancer Signal Detected with the Galleri test
Patient Story: Roger, Cancer Signal Detected with the Galleri test
The Galleri test is available by prescription only. The Galleri test does not detect a signal for all cancers, and false positive or false negative results can occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.
Who is eligible?
The Galleri test valued at $949 is offered as an annual benefit at no cost to US-based Qualcomm employees and their spouse/domestic partner who are 50 years old or older or 35-49 with risk factors and who are enrolled in a Qualcomm Premier (PPO or QDHP), United Healthcare (QDHP) or Kaiser Permanente (QDHP) Health Plan. Available testing locations are dependent upon your medical plan. See below for more information.
Employees
- Enrolled in a Qualcomm Premier (PPO or QDHP), United Healthcare (QDHP) or Kaiser Permanente (QDHP) Health Plan
- Aged 50 years old or older
- Aged 35-49 with risk factors documented below
- 35-49 years old AND at least one of the following risk factors:
- Cancer survivor who has completed treatment at least 3 years ago*
- Currently smokes or quit smoking less than 10 years ago
- Diagnosis of cirrhosis or chronic hepatitis B or C infection
- Infection with certain strains of HPV (e.g., HPV 16 or 18)
- Known hereditary cancer syndrome
- Confirmation or documentation of a gene mutation associated with increased cancer risk (e.g., Li-Fraumeni syndrome, hereditary breast and ovarian cancer syndrome [BRCA1/2], Lynch syndrome, and CHEK2).
- 35-49 years old AND at least two of the following risk factors:
- Documented genetic predisposition (germline variant)
- First-degree relative with cancer†
- History of HIV infection
- Current use of immunosuppressive therapies after solid organ transplant
- Diabetes
- BMI:
- Female ≥ 30 kg/m2
- Male ≥ 35 kg/m2
- *Excludes basal or squamous cell carcinoma of the skin.
- †Excludes basal or squamous cell carcinoma of the skin and/or the second cancer is not a recurrence or metastasis.
- Please note that the Galleri test is not available for people who are currently pregnant or undergoing cancer treatment.
Dependents / Spouses
- Enrolled in a Qualcomm Premier (PPO or QDHP), United Healthcare (QDHP) or Kaiser Permanente (QDHP) Health Plan
- Aged 50 years old or older
- Aged 35-49 with risk factors documented below
- 35-49 years old AND at least one of the following risk factors:
- Cancer survivor who has completed treatment at least 3 years ago*
- Currently smokes or quit smoking less than 10 years ago
- Diagnosis of cirrhosis or chronic hepatitis B or C infection
- Infection with certain strains of HPV (e.g., HPV 16 or 18)
- Known hereditary cancer syndrome
- Confirmation or documentation of a gene mutation associated with increased cancer risk (e.g., Li-Fraumeni syndrome, hereditary breast and ovarian cancer syndrome [BRCA1/2], Lynch syndrome, and CHEK2).
- 35-49 years old AND at least two of the following risk factors:
- Documented genetic predisposition (germline variant)
- First-degree relative with cancer†
- History of HIV infection
- Current use of immunosuppressive therapies after solid organ transplant
- Diabetes
- BMI:
- Female ≥ 30 kg/m2
- Male ≥ 35 kg/m2
- *Excludes basal or squamous cell carcinoma of the skin.
- †Excludes basal or squamous cell carcinoma of the skin and/or the second cancer is not a recurrence or metastasis.
- Please note that the Galleri test is not available for people who are currently pregnant or undergoing cancer treatment.
Limited data exists regarding the performance of the Galleri test in individuals <50 years of age.2,3,4
Request Galleri
Galleri testing is available to eligible individuals through primary care providers at the Bay Area Qualcomm Health Center and at the San Diego Qualcomm Health Center. Premier Plan members can also receive testing with a Primary Care provider at any Scripps Clinic or Scripps Coastal location.
You can request Galleri testing when you schedule your annual preventative visit. If you recently completed your annual preventative care visit, a separate appointment (either virtual or in-person) must be scheduled to discuss and verify eligibility for the testing.
-
Which Qualcomm health plan do you have?
-
Which clinic do you want to visit?
Which clinic do you want to visit?
Which clinic do you want to visit?
-
Instructions: Please contact the concierge team at 844-884-7266 with questions or for help scheduling your visit.
Instructions: Please contact the Bay Area Qualcomm Health Center at 408-546-2000 for questions or assistance with scheduling.
Instructions: Please contact the Qualcomm Health Center at 858-651-5918 with questions or for help scheduling your visit.
Instructions: Please contact the Bay Area Qualcomm Health Center at 408-546-2000 for questions or assistance with scheduling.
Instructions: Please contact the Qualcomm Health Center at 858-651-5918 with questions or for help scheduling your visit.
Instructions: Please contact the Bay Area Qualcomm Health Center at 408-546-2000 for questions or assistance with scheduling.
What does the Galleri test result mean?
The Galleri test detected DNA fragments associated with cancer in your blood sample. About 1 out of every 100 test has a Cancer Signal Detected result.4
This result will also include a prediction of the issue type or organ associated with the cancer signal, called a Cancer Signal Origin (CSO). This provides direction to your doctor on the cancer’s origin and can help guide the next steps for diagnosis.2,5
In a clinical study, around 6 out of 10 people with a Cancer Signal Detected result were diagnosed with cancer after diagnostic testing.6*
*Based on the first ~25,000 participants with 1 year of follow-up.
The Galleri test does not detect a signal for all cancers, and false positive or false negative results can occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.
NEXT STEPS
A Cancer Signal Detected test result is not a cancer diagnosis and requires follow-up diagnostic testing. Such testing may include lab work or imagining ordered by your healthcare provider to confirm cancer.
The Galleri test did not detect DNA fragments associated with cancer in your blood sample.
Nearly 99% of people who use the Galleri test will screen negative.4
This result does not completely rule out the possibility of cancer. While the Galleri test is a powerful tool, it cannot detect a signal for all cancers and not all cancers can be detected in the blood. Some cancers shed little or no DNA into the bloodstream, making them unlikely to be detected through a blood test (e.g., brain, skin, and early-stage breast and prostate cancers).7 False positive and false negative results do occur. This result does not predict whether you will develop cancer in the future.
NEXT STEPS
Continue with any routine cancer screenings your healthcare provider recommends. Do not ignore cancer signs or symptoms if they occur, as this could lead to delayed diagnosis.
Cancer can be unpredictable. The Galleri test can be taken as a simple blood test. Adding the Galleri test to an annual routine can improve your chance of finding cancer early.8
Cancer screening with Galleri can make a difference
-
Patient testimonial: Jackie
Cancer Signal Detected
Read Jackie's full story -
Patient testimonial: Cindy
Cancer Signal Detected
-
Patient testimonial: Jonathan
Cancer Signal Detected
-
Patient testimonial: Rich
Cancer Signal Detected
-
Patient testimonial: Mary
Cancer Signal Detected
-
Patient testimonial: Roger
Cancer Signal Detected
-
Patient testimonial: Valerie
Cancer Signal Detected
-
Patient testimonial: Tami
No Cancer Signal Detected
-
Patient testimonial: Keith
No Cancer Signal Detected
-
Patient testimonial: Jennifer
No Cancer Signal Detected
Read Jennifer's full story -
Patient testimonial: Rich & Staci
Cancer Signal Detected
Read Rich & Staci's full story -
Oncologist Perspectives
Frequently Asked Questions for Qualcomm
The Galleri test valued at $949 is offered as an annual benefit at no cost to US-based Qualcomm employees and their spouse/domestic partner who are 50 years old or older or 35-49 with risk factors and who are enrolled in a Qualcomm Premier (PPO or QDHP), United Healthcare (QDHP) or Kaiser Permanente (QDHP) Health Plan.
Galleri testing is available to eligible individuals through primary care providers at the Bay Area Qualcomm Health Center and at the San Diego Qualcomm Health Center. Premier Plan members can also receive testing with a Primary Care provider at any Scripps Clinic or Scripps Coastal location.
You can request Galleri testing when you schedule your annual preventative visit. If you recently completed your annual preventative care visit, a separate appointment (either virtual or in-person) must be scheduled to discuss and verify eligibility for the testing.
Individuals on a Qualcomm Premier (PPO or QDHP) Health Plan:
- To visit the San Diego Qualcomm Health Center or any Scripps Clinic or Scripps Coastal location contact the concierge team at 844-884-7266 with questions or for help scheduling your visit.
- To visit the Bay Area Qualcomm Health Center call 408-546-2000 for questions or assistance with scheduling.
Individuals on a United Healthcare (QDHP) Health Plan:
- To visit the San Diego Qualcomm Health Center call 858-651-5918 for questions or assistance with scheduling.
- To visit the Bay Area Qualcomm Health Center call 408-546-2000 for questions or assistance with scheduling.
Individuals on a Kaiser Permanente (QDHP) Health Plan:
- To visit the San Diego Qualcomm Health Center call 858-651-5918 for questions or assistance with scheduling.
- To visit the Bay Area Qualcomm Health Center call 408-546-2000 for questions or assistance with scheduling.
The cost of the Galleri test, blood draw, and laboratory fees are all covered under this benefit.
Under the Qualcomm benefit program, employees and spouses/domestic partners are eligible for benefit coverage of the Galleri test every year.
Get support
By email: customerservice@grail.com
By telephone: (833) 694‑2553
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes
- US Preventive Services Task Force. A,B,C grade recommendations, cancer, screening [cited 2025 Mar 18]. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results
- Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806
- Matrana M, Shukla V, Kingsbury D, et al. Real‑world data and clinical experience from over 100,000 multi‑cancer early detection tests [poster]. American Association for Cancer Research (AACR) Annual Meeting; 2025 Apr 25-30; Chicago. https://assets.grail.com/wp-content/uploads/2025/04/7202.Matrana.AACR-2025-RWE-100K_Poster_Final.pdf
- Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402(10409):1251-60. doi: 10.1016/S0140-6736(23)01700-2
- GRAIL, Inc. Enhanced Cancer Signal Origin prediction. [Data on file: VV-TMF-59592]
- Nabavizadeh N, et al. Safety and performance of a multi-cancer early detection (MCED) test in an intended-use population: initial results from the registrational PATHFINDER2 study [proffered presentation]. European Society for Medical Oncology (ESMO) Annual meeting: 2025 Oct 17-21; Berlin.
- Bredno J, Venn O, Chen X, et al. Circulating tumor DNA allele fraction: a candidate biological signal for multi-cancer early detection tests to assess the clinical significance of cancers. Am J Pathol. 2022; 192(10):1368-78. doi:10.1016/j.ajpath.2022.07.007
- Sasieni P, Clarke CA, Hubbell E. Impact of MCED screening interval on reduction in late-stage cancer diagnosis and mortality. European Society for Medical Oncology (ESMO) Virtual Congress [poster]; 2021 Sep 16-21.